Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ENTPD2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ENTPD2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ENTPD2 Products |
| Gene Delivery | ENTPD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ENTPD2 Products |
| Benchmark Ab | Anti-ENTPD2 Recombinant Antibody Recombinant positive control for assay validation. |
View ENTPD2 Products |
| Validator | ENTPD2 siRNA Set For knockdown verification. |
View ENTPD2 Products |
| Related Target A | ENTPD1 (CD39) Major ectonucleotidase in the purinergic pathway; critical counter-screening target. |
View ENTPD1 Products |
| Related Target B | NT5E (CD73) Downstream ectonucleotidase converting AMP to immunosuppressive adenosine. |
View NT5E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against ENTPD family members | Sequence-verified ENTPD1, ENTPD2, and ENTPD3 recombinant proteins available with >95% purity. |
| Conformational integrity for membrane-bound enzyme assays | Lentiviral vectors optimized for stable cell line expression, preserving native membrane topology. |
| High background noise in enzymatic assays | Endotoxin-controlled, low-aggregate protein preparations to ensure reliable assay baselines. |
| Lack of clinical benchmark controls | Sequence-verified benchmark antibodies generated from clinical pipeline leads. |
Live ENTPD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the purinergic signaling pathway is a rapidly expanding frontier in cancer immunotherapy. ENTPD2 (Ectonucleoside triphosphate diphosphohydrolase 2, also known as CD39L1) preferentially hydrolyzes extracellular ATP to ADP, playing a distinct role from ENTPD1 (CD39) in regulating the balance of extracellular nucleotides. Because extracellular ADP regulates immune cell infiltration and platelet activation, selectively targeting ENTPD2 offers a unique therapeutic window, particularly in hepatocellular carcinoma (HCC) and other solid tumors where ENTPD2 is highly upregulated on cancer-associated fibroblasts (CAFs).
As the clinical limitations of pan-CD39 inhibitors become apparent—specifically regarding systemic bleeding risks and broad immunosuppression—the industry is actively pivoting toward target-selective monoclonal antibodies and small molecule inhibitors. The next wave of R&D focuses on combining selective ENTPD2 inhibition with PD-1/PD-L1 blockade to overcome myeloid-derived suppressor cell (MDSC) mediated resistance in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Innate Pharma, Surface Oncology | Hepatocellular Carcinoma, Glioma | High-purity ECD-Fc proteins for epitope mapping and binding kinetics. |
| Small Molecule Inhibitor | Academic institutions, Biotech startups | Solid Tumors, Inflammatory Diseases | Enzymatic activity assays requiring high-purity, low-endotoxin recombinant ENTPD2. |
| Combination Therapy | Major Pharmaceutical Consortia | Refractory Solid Tumors | Lentivirus for stable cell-line construction to evaluate combination efficacy in vitro. |